Mr Market is saying about the same thing as it did assigning value to Amarin prior to Amarin’s topline. Mr Market blew that one completely even though Jelis data was well known. Their market cap is 8 Billion C now . I believe that RVX is powered to robustly detect a 30% or better RRR; thus achieving that or more would put us in the same market cap universe neighborhood,  with CKD and AD potentially piling value on. Another situation to look at is the Novavax vaccine program that Novavax had the FDA do its own internal unblinded interim informational analysis during the current blinded RSV trial with a 30% cutoff hurdle... the FDA told them they achieved it; Novavax doesnt know by much they cleared the hurdle by but it was at least 30% effective , and the trial continues for readout early 2019.